Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination with Cisplatin and 5-Fluorouracil versus Placebo in Combination with Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects with Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Feb 2024
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Fluorouracil (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms KEYNOTE-590
- Sponsors Merck Sharp & Dohme Corp.
- 20 Jan 2024 Results assessing 5-yr follow-up data of First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer presented at the 2024 Gastrointestinal Cancers Symposium
- 20 Jan 2024 Results of post hoc, exploratory analysis assessing the efficacy of 1L pembro + chemo in the GEJC and EAC subgroups of KEYNOTE-590 and the GEJ subgroup of KEYNOTE-859 presented at the 2024 Gastrointestinal Cancers Symposium.
- 24 Jul 2023 Status changed from active, no longer recruiting to completed.